Overview of present day treatment of Parkinson's disease
Identifieur interne : 002C02 ( Main/Exploration ); précédent : 002C01; suivant : 002C03Overview of present day treatment of Parkinson's disease
Auteurs : D. Yahr [États-Unis]Source :
- Journal of Neural Transmission [ 0300-9564 ] ; 1978-09-01.
Abstract
Summary: In the light of present day knowledge, augmenting striatal dopaminergic activity is the most effective means for controlling the symptoms of parkinsonism. This is best accomplished by the administration of levodopa with a peripheral decarboxylase inhibitor. However, limitations in its benefits develop after long-term administration in a substantial number of patients. In an attempt to overcome these a number of pharmacological agents acting on striatal dopaminergic mechanisms have undergone clinical trial. Of those tried Deprenyl, an MAO-B inhibitor, given with levodopa and carbidopa has shown the most promise. Preliminary results in 35 patients indicate that it is useful in diminishing the incidence of “on-off” phenomena—one of the most limiting reactions to levodopa—as well as enabling some patients to recoup their loss of therapeutic benefits. Though far from resolving all of the therapeutic difficulties encountered with prolonged use of levodopa, it appears to be a valuable adjunctive agent for the long-term problem patient.
Url:
DOI: 10.1007/BF01246959
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of present day treatment of Parkinson's disease</title><author><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:29CC8D95EFB65F502E6E28CE0B03254BBB1638B0</idno><date when="1978" year="1978">1978</date><idno type="doi">10.1007/BF01246959</idno><idno type="url">https://api.istex.fr/document/29CC8D95EFB65F502E6E28CE0B03254BBB1638B0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001791</idno><idno type="wicri:Area/Main/Curation">001548</idno><idno type="wicri:Area/Main/Exploration">002C02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Overview of present day treatment of Parkinson's disease</title><author><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mt. Sinai School of Medicine, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1978-09-01">1978-09-01</date><biblScope unit="volume">43</biblScope><biblScope unit="issue">3-4</biblScope><biblScope unit="page" from="227">227</biblScope><biblScope unit="page" to="238">238</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">29CC8D95EFB65F502E6E28CE0B03254BBB1638B0</idno><idno type="DOI">10.1007/BF01246959</idno><idno type="ArticleID">Art5</idno><idno type="ArticleID">BF01246959</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: In the light of present day knowledge, augmenting striatal dopaminergic activity is the most effective means for controlling the symptoms of parkinsonism. This is best accomplished by the administration of levodopa with a peripheral decarboxylase inhibitor. However, limitations in its benefits develop after long-term administration in a substantial number of patients. In an attempt to overcome these a number of pharmacological agents acting on striatal dopaminergic mechanisms have undergone clinical trial. Of those tried Deprenyl, an MAO-B inhibitor, given with levodopa and carbidopa has shown the most promise. Preliminary results in 35 patients indicate that it is useful in diminishing the incidence of “on-off” phenomena—one of the most limiting reactions to levodopa—as well as enabling some patients to recoup their loss of therapeutic benefits. Though far from resolving all of the therapeutic difficulties encountered with prolonged use of levodopa, it appears to be a valuable adjunctive agent for the long-term problem patient.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Yahr, D" sort="Yahr, D" uniqKey="Yahr D" first="D." last="Yahr">D. Yahr</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:29CC8D95EFB65F502E6E28CE0B03254BBB1638B0
|texte= Overview of present day treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |